Erythropoietic Protoporphyria (EPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Erythropoietic Protoporphyria (EPP) Market Outlook
Thelansis’s “Erythropoietic
Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Erythropoietic
Protoporphyria (EPP) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Erythropoietic Protoporphyria (EPP)
Overview
Erythropoietic
protoporphyria is a genetic condition that affects heme production, which leads
to the overproduction of protoporphyrin, mainly in the bone marrow. This
condition leads to higher levels of the heme precursor excreted in the bile. In
some cases, this disorder progresses to liver disease and eventually ends with
liver transplantation. Since the bone marrow continues to produce excessive
protoporphyrin after the transplant, the condition can recur in the
transplanted liver. As a result, liver transplantation, while a potential
treatment, tends to be a palliative measure rather than a cure due to the risk
of recurrence. EPP can result from mutations of the ferrochelatase gene (FECH).
Children develop pain, redness, swelling, pruritus, and a variety of
hepatobiliary complications. Approximately 5%–10% of subjects have an X-linked
variant of EPP (termed XLPP), resulting from a gain-of-function mutation in the
Alas2 gene.41 Mild microcytic anemia occurs in 20%–60% of patients with some
evidence of iron deficiency.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment